Entellus Medical Inc. (NASDAQ:ENTL) VP Margaret A. Boiano sold 11,103 shares of the stock in a transaction on Thursday, October 13th. The shares were sold at an average price of $20.01, for a total value of $222,171.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Entellus Medical Inc. (NASDAQ:ENTL) traded up 3.98% during mid-day trading on Friday, reaching $20.40. The company’s stock had a trading volume of 50,135 shares. Entellus Medical Inc. has a 12 month low of $13.72 and a 12 month high of $22.63. The company’s 50-day moving average is $20.09 and its 200 day moving average is $18.19. The firm’s market cap is $384.52 million.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Wednesday, August 3rd. The medical technology company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.08. The firm earned $18.73 million during the quarter, compared to analyst estimates of $18.48 million. Entellus Medical had a negative net margin of 33.54% and a negative return on equity of 41.83%. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.15) EPS. On average, equities analysts anticipate that Entellus Medical Inc. will post ($1.23) EPS for the current year.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Several hedge funds have recently bought and sold shares of ENTL. Schwab Charles Investment Management Inc. increased its stake in Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock worth $312,000 after buying an additional 210 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Entellus Medical by 2.2% in the second quarter. Ameriprise Financial Inc. now owns 75,048 shares of the medical technology company’s stock worth $1,370,000 after buying an additional 1,612 shares in the last quarter. Teachers Advisors Inc. increased its stake in Entellus Medical by 21.7% in the second quarter. Teachers Advisors Inc. now owns 10,533 shares of the medical technology company’s stock worth $192,000 after buying an additional 1,876 shares in the last quarter. Geode Capital Management LLC increased its stake in Entellus Medical by 8.2% in the first quarter. Geode Capital Management LLC now owns 41,648 shares of the medical technology company’s stock worth $757,000 after buying an additional 3,160 shares in the last quarter. Finally, State Street Corp increased its stake in Entellus Medical by 7.9% in the first quarter. State Street Corp now owns 50,773 shares of the medical technology company’s stock worth $923,000 after buying an additional 3,714 shares in the last quarter. 66.22% of the stock is owned by institutional investors.

A number of analysts recently weighed in on the company. Bank of America Corp. restated a “buy” rating on shares of Entellus Medical in a report on Monday, July 18th. Canaccord Genuity restated a “buy” rating and issued a $23.00 price objective on shares of Entellus Medical in a report on Friday, August 5th. BTIG Research restated a “buy” rating and issued a $22.00 price objective on shares of Entellus Medical in a report on Friday, August 5th. Zacks Investment Research downgraded Entellus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. Finally, Deutsche Bank AG assumed coverage on Entellus Medical in a report on Thursday, October 6th. They issued a “buy” rating and a $26.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $22.75.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

5 Day Chart for NASDAQ:ENTL

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.